The New Capital of Care in Rare Disease

A quiet revolution is underway in how biomedical innovation gets funded, and it has little to do with the traditional playbook. Venture capital, long the dominant engine of drug development, was never really built for rare disease. The returns simply don’t scale to the fund sizes venture capitalists need to justify the effort. But in its place, a new class of investors and financial structures are stepping forward, ones that blend patience with purpose and are proving remarkably well-suited to the particular demands of developing therapies for small patient populations.

The shift runs deeper than sentiment or circumstance. It reflects a fundamental mismatch between how capital has historically been deployed and what rare disease development actually requires. Understanding why it’s happening, and where it’s headed, means rethinking some basic assumptions about what biotech investment is actually for.

The limits of the old model

Venture capital operates on a well-worn logic. It makes large bets on single assets, absorbs a high failure rate and relies on one blockbuster return to justify the rest. For common diseases affecting enormous patient populations, this math can work. For ultrarare diseases that affect only dozens, hundreds or a few thousand people worldwide, it almost never does.

The entire venture capital framework of writing hundred-million-dollar checks, 10-year fund cycles, and pressure toward initial public offerings (IPOs) or acquisition was simply never designed for the biology and economics of rare disease development. This isn’t a case in which the model is broken. It’s a case in which the model was never designed for this problem in the first place.

What’s emerging to fill the gap isn’t a single alternative but a layered ecosystem of capital, each tier suited to a different stage of the development journey.

Community capital and the patient-led foundation

At the earliest stages, funding for rare diseases is increasingly coming from the community itself. Regulation Crowdfunding (Reg CF), which allows companies to raise capital from nonaccredited investors through Securities and Exchange Commission-regulated platforms, has become a viable on-ramp for companies whose mission resonates more broadly than traditional investors might reach. Donors and investors in these rounds are typically contributing modest amounts, often motivated more by connection to the disease or the people than by financial return expectations. The aggregate effect, however, is real. It can generate early-stage capital, build community ownership and create a base from which more substantial investors can follow.

Family foundations tied to specific rare diseases operate similarly, often licensing intellectual property and reinvesting royalties into further research. The Cystic Fibrosis Foundation’s model is where patient advocacy directly funds the development of a transformative therapy and then captures royalties to fund the next generation of research. This has become a template others are actively pursuing.

Family offices: Patient capital with purpose

The second and perhaps most consequential new player is the family office. These private wealth management structures manage assets for high-net-worth individuals and multigenerational families.

Unlike venture funds, family offices don’t operate under the pressure of a fixed return timeline. They can write checks in the $500,000 to $5 million range, which may not seem like a lot to a traditional investor but is very meaningful for a rare disease company and manageable for a family office. Critically, they’re often motivated by impact as much as return. Many represent aging generations of wealth-seeking legacies that extend beyond philanthropy and into actual health outcomes.

What makes ultrarare disease an unexpectedly strong fit for family offices comes down to the underlying economics. Because these therapies target the genetic root cause of disease rather than managing symptoms, the development risk profile is fundamentally different. In addition, a portfolio-based approach, spreading investment across multiple assets, further reduces that risk. Small patient populations, far from being a liability, actually command premium pricing, which produces margins that can be surprisingly robust relative to development costs. Those smaller development costs also mean that meaningful participation doesn’t require the nine-figure commitments that define venture capital. And because ultrarare disease companies are increasingly able to commercialize their own therapies — reaching patients directly without a Big Pharma acquirer — the exit landscape looks different too. Exits can now include IPOs, royalty streams and dividends rather than a buyout or licensing deal. For family offices, that’s a more legible and controllable path to return.

HoldCo/OpCo: Restructuring how innovation scales

Perhaps the most architecturally novel development is the rise of HoldCo/OpCo structures in biotech. This model separates asset acquisition from operational execution, similar to how real estate investment trusts separate real estate ownership from property management.

In this model, a holding company acquires promising drug assets, often at distressed prices, including the large inventory of shelved or paused programs that have accumulated across the industry. They then partner with or create operating companies that have the specialized expertise to advance those assets through development and to market.

What makes the OpCo model work is the tight integration of scientific, clinical and commercial capabilities running in parallel across a diversified asset portfolio. Because the OpCo doesn’t bet everything on a single compound, it can maintain commercial and operational infrastructure that would be unjustifiable for a traditional single-asset startup. The result is something closer to an asset stack than a single bet, where each individual asset carries meaningful risk, but the full portfolio approaches near-certain success for some subset of therapies.

Commercialization models are also shifting as a result. For genetic diseases, the patient population is already identified and accessible through genomic diagnostic companies like GeneDx, Invitae and Genomics England, which have effectively premapped the market. In the case of ultrarare genetic diseases, depending on the therapeutic modality, as few as 30 to 50 known patients can be enough to justify an initial commercial launch, a scale that demands intimacy and precision rather than infrastructure. A commercial team of five to 10 people can reach the entire relevant market simply by building relationships with a small network of specialists, hospitals and payers. There are no armies of sales representatives needed, no vast distribution infrastructure. The traditional justification for selling to Big Pharma to commercialize because “we’re too small” is dissolving.

A new trajectory

Together, these three forces — community-driven early capital, family office patient investment and HoldCo/OpCo operational structures — describe a funding journey that is increasingly self-contained and coherent.

The broader implication may be the most significant part of the story. Rare diseases, taken together, are far from rare; they affect hundreds of millions of people globally. And as medicine grows more precise, common diseases are increasingly understood as collections of distinct (“rare”) subtypes, each with its own biology and treatment logic. Cancer is already there.

The clinical trial infrastructure that served mass-market medicine for decades is overdue for disruption, and the investors driving change in rare disease today may be the ones who end up sketching the blueprint for what sustainable, purpose-aligned biotech looks like across all of medicine.

Rob Freishtat, M.D., is a strategic adviser and life science consultant, and Casey McPherson is founder and CEO of AlphaRose Therapeutics